Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients - Full Text View

Purpose

Several studies from HIV-NAT have demonstrated high nevirapine, indinavir, saquinavir and lopinavir/r levels when compared to Caucasian patients. Until now, the pharmacokinetics of atazanavir have not been explored in a Thai population. We postulate that ATV levels, as with other PIs, are higher in Thai people. Therefore, the level of ATV in ATV/RTV 300/100 OD may be higher than the acceptable range and could be associated with ATV related toxicity.

Condition	Intervention	Phase
HIV Infections	Drug: Atazanavir	Phase I Phase II

MedlinePlus related topics:

AIDS

ChemIDplus related topics:

Ritonavir Atazanavir sulfate BMS 232632

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Pharmacokinetics Study

Official Title:	The Pharmacokinetics of Atazanavir / Ritonavir 200/100 OD Versus 300/100 mg OD in Combination With 2 NRTIs in HIV Pre-Treated Patients

Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:

Primary Outcome Measures:

the pharmacokinetics of atazanavir/ritonavir (ATV/RTV) 200/100 mg once daily in a sample of 22 patients experiencing virological success [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

The pharmacokinetic and pharmacodynamic between these patients and data from Thai cohort treated with ATV/RTV 300/100 mg OD [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
short term safety, tolerability and efficacy data in these PK participating patients [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment:	22
Study Start Date:	January 2007
Study Completion Date:	January 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator ATV/r 300/100 mg	Drug: Atazanavir ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
2: Active Comparator ATV/r 200/100 mg OD	Drug: Atazanavir ATV/r 300/100mg OD vs ATV/r 200/100 mg OD

Detailed Description:

We are interested in once daily ATV/RTV 200/100 mg OD because of the convenience, reduction in ATV doses which may improve adherence while reducing toxicity and cost. There are limited prospective studies evaluating pharmacokinetic and long term efficacy and safety of atazanavir/ritonavir once daily dose in combination of NRTIs in HIV-1 pretreated patients. We believe that the PK parameters of ATV/RTV given at 200/100mg daily in Thai patients will be equivalent to the ATV/RTV 300/100mg once daily dosing in Caucasian patients when combined with 2NRTIs, and that the once daily regimen will have better safety, tolerability profile, and cost saving while maintaining good CD4 and VL outcome. If, the pharmacokinetic profile of ATV/RTV 200/100 mg OD + 2NRTIs is in acceptable range or comparable with standard dose of ATV/RTV 300/100 mg OD, long term efficacy will be explored later.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Written informed consent
Adults HIV patients currently using ATV/RTV 300/100 mg OD plus 2 NRTIs
HIV RNA < 50 copies/ml

Exclusion Criteria:

Inability to understand the nature and extent of the study and the procedures required.
ALT/ AST more than 5x upper limit
Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.
Use of concomitant medication that may interfere with the pharmacokinetics of atazanavir, and ritonavir
History of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study.
Active drug abuse or heavy alcoholic drinking
History of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study.
Active drug abuse or heavy alcoholic drinking

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00411957

Locations


Thailand
	HIV-NAT, Thai Red Cross AIDS Research Center
	Bangkok, Thailand, 10300

Sponsors and Collaborators

The HIV Netherlands Australia Thailand Research Collaboration

Bristol-Myers Squibb

Investigators


Principal Investigator:	Kiat Ruxrungtham, MD	HIV-NAT Thai Red Cross AIDS Research Center

More Information

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) This link exits the ClinicalTrials.gov site

Responsible Party:	HIV-NAT ( Kiat Ruxrungtham )
Study ID Numbers:	HIV-NAT 073
First Received:	December 13, 2006
Last Updated:	March 13, 2008
ClinicalTrials.gov Identifier:	NCT00411957
Health Authority:	Thailand: Food and Drug Administration

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:

atazanavir/ritonavir

pharmacokinetic of ATV/r200/100 OD+2NRTIs

Study placed in the following topic categories:

Virus Diseases

Sexually Transmitted Diseases, Viral

Ritonavir

HIV Infections

Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome

Atazanavir

Retroviridae Infections

Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Anti-Infective Agents

RNA Virus Infections

HIV Protease Inhibitors

Slow Virus Diseases

Anti-HIV Agents

Immune System Diseases

Molecular Mechanisms of Pharmacological Action

Enzyme Inhibitors

Infection

Antiviral Agents

Pharmacologic Actions

Protease Inhibitors

Anti-Retroviral Agents

Therapeutic Uses

Lentivirus Infections

ClinicalTrials.gov processed this record on October 15, 2008

Sponsors and Collaborators:	The HIV Netherlands Australia Thailand Research Collaboration Bristol-Myers Squibb
Information provided by:	The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier:	NCT00411957